Three Pharma Companies Launch Favipiravir to Treat COVID-19 in India

 Three Pharma Companies Launch Favipiravir to Treat COVID-19 in India

Three Pharma Companies Launch Favipiravir to Treat COVID-19 in India

Shots:

  • Jenburkt became the second company to launch Favivent (favipiravir) to treat mild to moderate COVID-19 symptoms at a price of ​Rs. 39/tablet
  • Cipla receives the DCGI approval for Ciplenza (favipiravir, 200mg) targeting the unmet medical needs for COVID-19 treatment options in the country through restricted emergency use. The company will launch Ciplenza in the first week of August priced at Rs 68/ tablet
  • Moreover, Brinton gets DCGI approval drug favipiravir under the brand name Faviton (Rs 59/ tablet) for the treatment of COVID-19 patients. Faviton is a generic version of Avigan of Fujifilm Toyama, a subsidiary of Fujifilm Corporation

Cipla, Jenburkt, Brinton­ read full press release/ article | Ref: Cipla, Jenburkt, Brinton | Image: Pharmashots

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post